Manufacturing Pluripotent Stem Cells And Their Derivatives For Clinical Applications — Learnings From France

Human pluripotent stem cells (PSCs) and their derivatives hold great potential in regenerative cell therapies and recently have been used in a number of clinical trials targeting various diseases. For example, PSC-derived retinal pigment epithelial (RPE) cells have been tested in the clinical trials for age-related macular degeneration and retinitis pigmentosa.

In this webinar, Chao Sheng will first introduce an established workflow for GMP-compliant human PSC expansion using the CliniMACS Prodigy® Adherent Cell Culture process and the iPS-Brew GMP Medium.

Afterward, Christelle Monville will introduce the work done on developing a novel tissue-engineered product (TEP) consisting of RPE cells derived from clinical-grade human embryonic stem cells. These cells were disposed on a biocompatible substrate allowing the formation of a 3D functional sheet, suitable for transplantation.

You will learn:

• How to produce pluripotent stem cells derived progenies for clinical applications
• How to upscale pluripotent stem cells derived progenies for GMP applications
• How to realize GMP-compliant PSC expansion using the closed and automated CliniMACS Prodigy